Developer of a drug development platform designed to apply computational tissue to biomarkers. The company's platform leverages the benefits of tissue-based biomarkers while reducing the risk and time associated with relying on a pathology-based patient selection strategy by integrating wet assay and image analysis to understand the biological content that determines patient phenotype and drug response, enabling drug developers to access advanced technology and scientific strategy to accelerate their drug approval by providing the necessary context.